Company Overview of The Wistar Institute
The Wistar Institute is an educational institution.
3601 Spruce Street
Philadelphia, PA 19104
Key Executives for The Wistar Institute
President and Chief Executive Officer
Director of Communications
Chief Scientific Officer and Director of Cancer Center
Compensation as of Fiscal Year 2015.
The Wistar Institute Key Developments
OncoCyte Corporation and The Wistar Institute Enter into Global Licensing Agreement
Jan 27 16
OncoCyte Corporation and The Wistar Institute have entered into a definitive global licensing agreement for a simple, non-invasive, blood test to aid physicians in the early detection of lung cancer. The agreement provides OncoCyte the exclusive rights to commercialize this lung cancer diagnostic test. Since 2013, OncoCyte and Wistar have been collaborating on product development of the lung cancer diagnostic test. In 2015, positive interim clinical results demonstrating the high level of observed sensitivity and specificity in the assayed samples of a prototype blood test for lung cancer were presented at the American Thoracic Society International Conference. Now, both parties are finalizing this assay, which is intended to serve as a confirmatory test for patients who are at risk for lung cancer (based on a patient’s positive or suspicious results identified by low dose computed tomography (LDCT) screening). If successful scientific and technical results are achieved, OncoCyte will proceed to the test’s final validation with the goal of completing work in 2016 to enable its commercial launch.
The Wistar Institute Presents at IMPACT 2015 Capital Conference, Nov-04-2015 03:30 PM
Oct 21 15
The Wistar Institute Presents at IMPACT 2015 Capital Conference, Nov-04-2015 03:30 PM. Venue: The Ritz-Carlton Hotel, Philadelphia, Pennsylvania, United States. Speakers: Heather Steinman, VP for BD and Executive Director, Technology Transfer.
The Wistar Institute and OncoCyte Corporation Expand Collaboration to Develop Lung Cancer Diagnostic Test
Sep 4 15
The Wistar Institute and OncoCyte Corporation have expanded their collaboration to develop a non-invasive, blood-based test designed to aid physicians in the early detection of lung cancer. In October 2013, OncoCyte entered into a Sponsored Research Agreement with The Wistar Institute to develop and test potential lung cancer biomarkers identified by Dr. Louise Showe, Ph.D., professor in Wistar's Molecular and Cellular Oncogenesis Program. Under the new expanded agreement, OncoCyte and Wistar will continue their collaboration with the goal of developing a highly sensitive and specific diagnostic test for the early detection of lung cancer. Critical to the success of the next phase of the R&D program will be the analysis of an expanded patient sample set, the transition of sample analysis to a platform capable of commercial scale operations, confirmation of mRNA and miRNA expression, and completion of diagnostic test verification activities. Dependent on achieving successful scientific and technical results at this stage of development, OncoCyte and Wistar will proceed to final validation of the test with the goal of completing that work in 2016 to enable OncoCyte to commercially launch the lung diagnostic test. OncoCyte has exercised options to obtain exclusive licenses to any inventions, discoveries or technology developed in the course of the collaborative research and expects to finalize definitive license agreements with Wistar in the near future.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries